[{"data":1,"prerenderedAt":159},["ShallowReactive",2],{"drug-dulaglutide":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":33,"contraindications":69,"warnings":79,"renal":87,"monitoring":88,"interactions":89,"review":90,"examples":93,"atc":94,"iran":96,"links":103,"populations":119,"usApproval":154},"dulaglutide",1,{"fa":7,"en":8},"دولاگلوتاید","Dulaglutide","alimentary-metabolism",{"fa":11,"en":12},"آگونیست GLP-1 هفتگی","Weekly GLP-1 agonist",[14],{"name":15,"market":16},"Trulicity","US",[18,19,7],"trulicity","تروليسيتی",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":28,"refs":29},"pen","injection","sc","Single-dose pen 0.75 \u002F 1.5 \u002F 3 \u002F 4.5 mg in 0.5 mL",{"amount":5,"unit":27,"perUnit":27},"application",[16],[30],{"source":31,"section":32},"fda-trulicity","3",[34,53],{"id":35,"disease":36,"label":37,"population":40,"type":44,"unit":45,"dose":46,"refs":50},"t2","type-2-diabetes",{"fa":38,"en":39},"دیابت نوع ۲ — هفته‌ای یک بار: ۰٫۷۵ mg، سپس ۱٫۵ mg؛ حداکثر ۴٫۵ mg","Type 2 diabetes — once weekly: 0.75 mg, then 1.5 mg; max 4.5 mg",{"minAge":41},{"value":42,"unit":43},18,"year","notCalculated","mg",{"reason":47},{"fa":48,"en":49},"هفته‌ای یک بار زیرجلدی (نه روزانه). شروع ۰٫۷۵ mg؛ پس از ۴ هفته ۱٫۵ mg؛ در صورت نیاز هر دست‌کم ۴ هفته ۱٫۵ mg افزایش تا حداکثر ۴٫۵ mg.","Once WEEKLY SC (not daily). Start 0.75 mg; after 4 weeks 1.5 mg; if needed increase by 1.5 mg after at least 4 weeks, to a max of 4.5 mg.",[51],{"source":31,"section":52},"2.1",{"id":54,"disease":36,"label":55,"population":58,"type":44,"unit":45,"dose":62,"refs":66},"t2-child",{"fa":56,"en":57},"دیابت نوع ۲ کودک (۱۰ سال به بالا) — هفته‌ای ۰٫۷۵ mg، حداکثر ۱٫۵ mg","Type 2 diabetes, children ≥10 y — 0.75 mg weekly, max 1.5 mg",{"minAge":59,"maxAge":61},{"value":60,"unit":43},10,{"value":42,"unit":43},{"reason":63},{"fa":64,"en":65},"هفته‌ای یک بار ۰٫۷۵ mg؛ در صورت نیاز پس از دست‌کم ۴ هفته ۱٫۵ mg (حداکثر).","Once weekly 0.75 mg; if needed, 1.5 mg after at least 4 weeks (maximum).",[67],{"source":31,"section":68},"2.2",[70],{"id":71,"severity":72,"text":73,"refs":76},"mtc","block",{"fa":74,"en":75},"سابقه شخصی یا خانوادگی کارسینوم مدولاری تیروئید یا MEN 2؛ حساسیت جدی.","Personal or family history of medullary thyroid carcinoma or MEN 2; serious hypersensitivity.",[77],{"source":31,"section":78},"4",[80],{"text":81,"refs":84},{"fa":82,"en":83},"هشدار جعبه‌ای: تومور سلول C تیروئید در جوندگان.","Boxed warning: thyroid C-cell tumours in rodents.",[85],{"source":31,"section":86},"Boxed Warning",[],[],[],{"status":91,"reviewer":92,"date":92},"unverified",null,[],[95],"A10BJ05",{"status":97,"refs":98},"not-found",[99],{"source":100,"section":101,"url":102},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Dulaglutide",[104,108,112,116],{"kind":105,"url":106,"label":107},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=125469","BLA125469",{"kind":109,"url":110,"label":111},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309","FDA Trulicity",{"kind":113,"url":114,"label":115},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa614047.html","Dulaglutide Injection",{"kind":117,"url":118,"label":95},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A10BJ05",{"pregnancy":120,"lactation":129,"pediatric":137,"geriatric":145},{"level":121,"text":122,"quote":125,"refs":126},"caution",{"fa":123,"en":124},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Limited data with TRULICITY in pregnant women are not sufficient to determine a drug-associated risk for major birth defects and miscarriage.",[127],{"source":31,"section":128},"8.1",{"level":121,"text":130,"quote":133,"refs":134},{"fa":131,"en":132},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of dulaglutide in human milk, the effects on the breastfed infant, or the effects on milk production.",[135],{"source":31,"section":136},"8.2",{"level":121,"text":138,"quote":141,"refs":142},{"fa":139,"en":140},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of TRULICITY as an adjunct to diet and exercise to improve glycemic control in pediatric patients 10 years of age and older with type 2 diabetes mellitus have been established.",[143],{"source":31,"section":144},"8.4",{"level":146,"text":147,"quote":150,"refs":151},"ok",{"fa":148,"en":149},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness for TRULICITY have been observed between patients 65 years of age and older and younger adult patients.",[152],{"source":31,"section":153},"8.5",{"kind":155,"refs":156,"id":107},"BLA",[157],{"source":31,"section":158},"SPL approval \u002F marketing category",1792115178223]